TGFB1 and myeloid sarcoma: Supplementation of 1000 IU vitamin D3 per day for six months (vitamin D3, n = 17; placebo, n = 19) induced elevated circulating TGF-β1 levels, a potential indicator of vitamin D action in MS [20].